BAKER BROS. ADVISORS LP Q3 2019 Filing
Filed November 14, 2019
Portfolio Value
$14.7B
Holdings
109
Report Date
Q3 2019
Filing Type
13F-HR
All Holdings (109 positions)
| Stock | Value |
|---|---|
SGENEURSeattle Genetics, Inc. | $4.3B |
INCYIncyte Corporation | $2.4B |
ACADACADIA Pharmaceuticals Inc. | $1.5B |
ONCBeiGene, Ltd. | $1.4B |
ALXNAlexion Pharmaceuticals, Inc. | $808.8M |
AMRNAmarin Corporation plc | $629.8M |
—Genomic Health, Inc. | $627.0M |
BMRNBioMarin Pharmaceutical Inc. | $511.5M |
ASNDAscendis Pharma A/S | $326.6M |
NVTA1EURInvitae Corporation | $169.4M |
KODKodiak Sciences Inc. | $131.5M |
NBIXNeurocrine Biosciences, Inc. | $127.5M |
ARGXargenx SE | $116.2M |
HRTXHeron Therapeutics, Inc. | $111.3M |
MRTXEURMirati Therapeutics, Inc. | $101.8M |
MDGLMadrigal Pharmaceuticals, Inc. | $100.8M |
—MyoKardia, Inc. | $79.1M |
—Spark Therapeutics, Inc. | $72.9M |
1T7Tricida, Inc. | $60.8M |
RYTMRhythm Pharmaceuticals, Inc. | $58.5M |
1K0IGM Biosciences, Inc. | $55.8M |
—Ra Pharmaceuticals, Inc. | $55.5M |
CERSCerus Corporation | $55.4M |
—DBV Technologies S.A. | $47.4M |
—Principia Biopharma Inc. | $46.7M |
BCELAtreca, Inc. | $43.2M |
—GW Pharmaceuticals plc | $42.7M |
—Zymeworks Inc. | $42.4M |
—Audentes Therapeutics, Inc. | $42.3M |
NBIX 2.25 05/15/24Neurocrine Biosciences, Inc. | $42.1M |
IM8NInsmed Incorporated | $39.3M |
BCRXBioCryst Pharmaceuticals, Inc. | $36.5M |
ADPTAdaptive Biotechnologies Corporation | $36.0M |
KRYSKrystal Biotech, Inc. | $35.9M |
—Neoleukin Therapeutics, Inc. | $32.2M |
CBAYUSDCymaBay Therapeutics, Inc. | $29.2M |
ALLKGUSDAllakos Inc. | $26.7M |
KNSAKiniksa Pharmaceuticals, Ltd. | $23.8M |
MRUSMerus N.V. | $20.7M |
QUREuniQure N.V. | $20.4M |
URGNUroGen Pharma Ltd. | $17.8M |
AXSMAxsome Therapeutics, Inc. | $15.6M |
BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | $14.7M |
XNCRXencor, Inc. | $14.4M |
—Aimmune Therapeutics, Inc. | $14.1M |
PTGXProtagonist Therapeutics, Inc. | $14.1M |
—La Jolla Pharmaceutical Company | $13.7M |
—Idera Pharmaceuticals, Inc. | $13.3M |
AGLEUSDAeglea BioTherapeutics, Inc. | $13.2M |
ALKSAlkermes plc | $12.2M |
—Syros Pharmaceuticals, Inc. | $10.1M |
GBYSangamo Therapeutics, Inc. | $9.0M |
ASMBAssembly Biosciences, Inc. | $7.9M |
TPIVDEURMarker Therapeutics, Inc. | $7.7M |
APLSApellis Pharmaceuticals, Inc. | $7.6M |
CPRXCatalyst Pharmaceuticals, Inc. | $7.1M |
HOOKGBPHOOKIPA Pharma Inc. | $6.7M |
—Acorda Therapeutics, Inc. | $6.4M |
—Dermira, Inc. | $5.8M |
XBITXbiotech Inc. | $5.5M |
BDQMAlbireo Pharma, Inc. | $5.0M |
VSAREURAravive, Inc. | $5.0M |
MISTMilestone Pharmaceuticals Inc. | $5.0M |
ORTXUSDOrchard Therapeutics plc | $4.8M |
HALOHalozyme Therapeutics, Inc. | $4.7M |
NXTCNextCure, Inc. | $4.6M |
IFRXInflarx N.V. | $4.4M |
ANABAnaptysBio, Inc. | $4.0M |
—Achillion Pharmaceuticals, Inc. | $3.9M |
GLPGGalapagos NV | $3.8M |
—bluebird bio, Inc. | $3.7M |
NGMUSDNGM Biopharmaceuticals, Inc. | $3.5M |
MIRMMirum Pharmaceuticals, Inc. | $3.4M |
XLRNAcceleron Pharma Inc. | $3.3M |
—Menlo Therapeutics Inc. | $3.1M |
—Harpoon Therapeutics, Inc. | $2.9M |
VKTXViking Therapeutics, Inc. | $2.9M |
—Abeona Therapeutics Inc. | $2.9M |
GTHXEURG1 Therapeutics, Inc. | $2.9M |
—Dova Pharmaceuticals, Inc. | $2.9M |
—Bellicum Pharmaceuticals, Inc. | $2.8M |
YMABUSDY-mAbs Therapeutics, Inc. | $2.7M |
CRNXCrinetics Pharmaceuticals, Inc. | $2.6M |
—Cyclerion Therapeutics, Inc. | $2.5M |
—Spring Bank Pharmaceuticals, Inc. | $2.1M |
AUTLAutolus Therapeutics plc | $1.9M |
IDYAIDEAYA Biosciences, Inc. | $1.8M |
NTLAIntellia Therapeutics, Inc. | $1.7M |
—Molecular Templates, Inc. | $1.7M |
—Forty Seven, Inc. | $1.6M |
—Foamix Pharmaceuticals Ltd. | $1.5M |
CTMXCytomX Therapeutics, Inc. | $1.4M |
CCXIEURChemoCentryx, Inc. | $1.4M |
FLGTFulgent Genetics, Inc. | $1.3M |
MTNBEURMatinas BioPharma Holdings, Inc. | $1.3M |
LPTXEURLeap Therapeutics, Inc. | $1.1M |
RCUSArcus Biosciences, Inc. | $1.1M |
GLMDGalmed Pharmaceuticals Ltd. | $1.0M |
—Adamas Pharmaceuticals, Inc. | $883K |
—Constellation Pharmaceuticals, Inc. | $861K |
Page 1 of 2Next